1Dodd RY, Norari EP,Stramer SL. Current prevalence and incidence of infections disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 2002,42: 975-979.
2Vargo J, Smith K, Knott C, et al. Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA.Transfusion,2002,42:876-885.
3Jackson JB, Smith K, Knott C, et al. Sensitivity of the precleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J Clin Microbiol,2002,40:2387-2391.
4Busch MP, Kleinman SH. Nucleic acid amplification testing of blood donors for transfusion-transmitted infections disease: report of the Interorganizational task force on nucleic acid amplification testing of blood donors. Transfusion, 2000,40: 143-159.
5Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine: first of two parts-blood transfusion. N Engl J Med, 1999,340:438-447.
6Roback JD. CMV and blood transfusion. Revs Med Virology, 2002, 12:211-219.
7Heegaard ED, Brown KE. Human parvovims B19. Clin Microbiol Rev, 2002,15:485-505.
8Laub R, Strengers P. Parvoviruses and blood products. Pathol Biol (Paris),2002,15:485-505.
9Hayakawa F, lmada K, Towatari M, et al. Life-threatening human parvovims B19 infection transmitted by intravenous immune globulin. Br J Haematol,2002,118:1187-1189.
10Koenigbauer UF, Eastlund T, Day JM. Clinical illness due to parvovirus B10 infection after infusion of solven/detergent-treated pooled plasma. Transfusion, 2000,40: 1203-1206.
